ADCT · ADC Therapeutics SA
$1.22
+0.09 (+7.96%)
At close · Oct 5
Return incl. dividend (before tax)
Market Cap
$160.22M
Shares
127.67M
Volume · Oct 5
1.75M
Avg daily vol (3M)
1.37M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$1.13
Open$1.10
Day$1.06–1.14
52W close$0.96–4.88
Avg vol 30d1.5M
Short int5.4M · 4.2% float · 3.9d
Short vol59%
Last earningsAug 13, 2026
DataMay 2020–Oct 2026
Filing10-Q · Aug 13
Up next
Next earnings call
Oct 15, 2026
Est · unconfirmed
· in 1 wks
filed Aug 13, 2026
call held Jun 3, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
$79.58M
Trailing 12 months
Net income (TTM)
−$96.91M
Trailing 12 months
Revenue growth YoY
+2.2%
Year over year
Operating margin
-125.1%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-63.8%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+36.3%
Year over year · more shares
Price change (1Y)
-71.6%
Trailing year
Short interest
4.2%
Latest settlement · 3.9 days to cover
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Sell
Momentum
Very Weak
Sentiment
Neutral
Fundamentals
Strong
Quant / Vol
Very High
Market backdrop
VIX 15.3 · calm
Equity put/call 0.59
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−58%
below
Price vs 50-day avg
−1%
below
RSI (14)
46
neutral
MACD trend
Negative
52-week position
4%
near low
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−14%
trailing
6-month return
−70%
trailing
YTD return
−68%
this year
Relative strength
−83%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $1 › 200d $3 — 200d above 50d
Institutional flow
Distributing
-4% holders QoQ · +26 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
4.22% of float · ▼ -14.2% MoM · 3.9 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
113 holders — mid 3-yr range
Squeeze score
59
elevated · 0–100
Fundamentals
Revenue growth
+15%
Y/Y
EPS growth
+31%
Y/Y
Free cash flow
$-141.4M
Quant / Vol
risk profile
Volatility
94%
annualized · 1-yr
Max drawdown
−80%
past year
ATR
8.4%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the Earnings Call filed Mar 31, 2026
Peak annual revenues of ZYNLONTA in the U.S.
· peak annual
$600M – $1B
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−58%
Bearish
Price vs 50-day avg
−1%
Neutral
RSI (14)
46
Neutral
MACD trend
Negative
Bearish
52-week position
4%
Bearish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $1 › 200d $3 — 200d above 50d
Institutional flow
Distributing
-4% holders QoQ · +26 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
4.22% of float · ▼ -14.2% MoM · 3.9 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
113 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $1
Now $1 · 4%
Range high $5
vs 200-day avg -58%
vs 50-day avg -1%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted net loss non-GAAP | $36M | six months ended June 30, 2026 | — |
| Adjusted net loss per share, basic and diluted non-GAAP | $0.23 | Six Months Ended June 30, 2026 | — |
| Adjusted total operating expenses non-GAAP | $80.1M | six months ended June 30, 2026 | — |
| annualized estimated cost savings | $10M | second quarter 2026 | — |
| workforce reduction | 17% | second quarter 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Drug Manufacturers - Specialty & Generic — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ADCT
this stock
ADC Therapeutics SA
|
$160.22M | -68.0% | +14.9% | — | 4.2% |
|
TAK
Takeda Pharmaceutical Co Ltd
|
$60.23B | +14.6% | — | — | 0.1% |
|
GALDY
Galderma Group AG/ADR
|
$46.00B | -6.5% | — | — | 0.0% |
|
TEVA
Teva Pharmaceutical Industries Ltd
|
$45.67B | +26.7% | +4.3% | 64.3 | 2.7% |
|
HLN
Haleon plc
|
$40.72B | -13.0% | — | — | 0.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ADCT | -11.0% | -14.4% | -70.3% | -7.4% | -68.0% |
| SPY | -0.2% | -0.5% | +12.2% | +0.9% | +12.9% |
| vs SPY | -10.8% | -13.9% | -82.5% | -8.3% | -80.9% |